Feedback

[ 177 Lu]Lu-PSMA-617 (Pluvicto TM ): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer

ORCID
0000-0003-4198-1899
Affiliation
German Cancer Research Center (DKFZ), Service Unit Radiopharmaceuticals and Preclinical Studies, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
Hennrich, Ute;
Affiliation
Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany and German Cancer Research Center, 69120 Heidelberg, Germany
Eder, Matthias

In March 2022, [ 177 Lu]Lu-PSMA-617 (Pluvicto TM ) was approved by the FDA for the treatment of prostate cancer patients. Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other therapy options (such as inhibition of the androgen receptor pathway and taxane-based chemotherapy). [ 177 Lu]Lu-PSMA-617, which combines a PSMA-specific peptidomimetic with a therapeutical radionuclide, is used in a radioligand therapy that selectively delivers ionizing radiation to tumor cells, causing their death, while sparing the surrounding healthy tissue. In numerous clinical trials, the efficacy of [ 177 Lu]Lu-PSMA-617 was demonstrated.

Cite

Citation style:
Could not load citation form.

Rights

License Holder: © 2022 by the authors.

Use and reproduction: